Supigen New Tech Fund Acquires 12.5% Stake in Celemics via Third-Party Allotment at Deep Discount, Signaling Management Influence

Supigen New Technology Investment Association No.1 has become a major shareholder of Celemics with a 12.50% stake, holding 1,193,602 shares as of the report date, and this is a new filing.
The stake was acquired through a third-party allotment at 8,378 KRW per share, representing a discount of approximately 42.6% compared to the closing price of 14,600 KRW on the reporting date, raising significant dilution concerns for existing shareholders.
The total acquisition amount of about 10 billion KRW was funded by the fund's capital, and the filer plans to exercise voting rights and influence management decisions such as director appointments and capital changes.
This accumulation by a new technology investment fund warrants attention to potential mid- to long-term corporate value changes driven by management involvement rather than short-term price pressure.
[AI Summary]Supigen New Tech Fund acquired a 12.5% stake in Celemics at a deep discount, signaling management influence but causing substantial dilution for existing shareholders. While the capital injection eases short-term financial burdens, the risk of governance disputes and low transparency pose long-term investment risks.